A recent study found that Mertk-/- anti-tumor immunity in melanoma and brain cancer models was not solely mediated by MERTK deletion but required additional genetic changes that had been introduced during generation of the Mertk-/- mouse line [68]. This evidence concerns the gene MERTK and melanoma.